Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment

doi:10.3748/wjg.v29.i26.4120

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12679)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

140

WORD

HTML

10186

Figures (1-5)

497

Tables (1-1)

275

Sum=11129

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

213

Download

584

Sum=797

Jul 14, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 14, 2023; 29(26): 4120-4135
Published online Jul 14, 2023. doi: 10.3748/wjg.v29.i26.4120

Full Size Figure Download Figure

Figure 5 The conventional treatment and further treatment of irritable bowel syndrome patients. TCM: Traditional Chinese treatment; CBT: Cognitive behavioral treatment; HAD: Hospital Anxiety and Depression scale; IBS-QOL: Irritable Bowel Syndrome-Quality of Life Questionnaire; PAC-QOL: Patient Assessment of Constipation-Quality of Life Questionnaire; PAC-SYM: PAC-Symptoms Questionnaire; 7αC4: 7α-hydroxy-4-cholesten-3-one; 75-SeHCAT: 75-selenium homocholic acid taurine; TCA: Tricyclic Antidepressants; SSRI: Selective Serotonin Reuptake Inhibitors; IBS: Irritable bowel syndrome; IBS-C: IBS-constipation; IBS-D: IBS-diarrhea.

Citation: Huang KY, Wang FY, Lv M, Ma XX, Tang XD, Lv L. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol 2023; 29(26): 4120-4135
URL: https://www.wjgnet.com/1007-9327/full/v29/i26/4120.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i26.4120